Faculty

Back to Index
William Stohl, MD, PhD
Professor of Medicine
Chief, Division of Rheumatology
Medicine
HMR 711 Health Sciences Campus Los Angeles
+1 323 442 1959

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren's syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

American College of Physicians: Fellow (FACP), 2012

Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

University of Pennsylvania School of Medicine: Upjohn Award, 1979

Publications

Johnson J, Yeter K, Rajbhandary R, Neal R, Tian Q, Jian J, Fadle N, Thurner L, Liu C, Stohl W. Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study. Clin Rheumatol. 2016 Nov 9. View in: PubMed

Stohl W. Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells. Arthritis Rheumatol. 2015 Mar; 67(3):612-5. View in: PubMed

Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Tsuji W, Zack DJ. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015; 17(1):215. View in: PubMed

Sindhava VJ, Scholz JL, Stohl W, Cancro MP. APRIL mediates peritoneal B-1 cell homeostasis. Immunol Lett. 2014 Aug; 160(2):120-7. View in: PubMed

Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, Renduchintala K, Zhu J, Bricel S, Silka K, Bach D, Heur M, Christianakis S, Arkfeld DG, Irvine J, Mack WJ, Stohl W. Tear Cathepsin S as a Candidate Biomarker for Sjögren's Syndrome. Arthritis Rheumatol. 2014 Jul; 66(7):1872-81. View in: PubMed

Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, Chen H, Lee SH, Leung I, Bonzon C, Desjarlais JR, Stohl W, Szymkowski DE. Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fc? Receptor IIb Inhibitory Receptor. Arthritis Rheumatol. 2014 May; 66(5):1153-64. View in: PubMed

Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014 Apr; 18(4):473-89. View in: PubMed

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9. View in: PubMed

Goenka R, Matthews AH, Zhang B, O'Neill PJ, Scholz JL, Migone TS, Leonard WJ, Stohl W, Hershberg U, Cancro MP. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014 Jan 13; 211(1):45-56. View in: PubMed

Stohl W. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013 Dec; 9(12):705-20. View in: PubMed

Shah HB, Joshi SK, Rampuria P, Devera TS, Lang GA, Stohl W, Lang ML. BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand. J Immunol. 2013 Aug 1; 191(3):1154-63. View in: PubMed

Kawatkar AA, Hay JW, Stohl W, Nichol MB. Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23. View in: PubMed

Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89. View in: PubMed

Jacob CO, Yu N, Guo S, Jacob N, Quinn WJ, Sindhava V, Cancro MP, Goilav B, Putterman C, Migone TS, Stohl W. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013 Apr; 65(4):1043-54. View in: PubMed

Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303. View in: PubMed

Kong N, Lan Q, Chen M, Zheng T, Su W, Wang J, Yang Z, Park R, Dagliyan G, Conti PS, Brand D, Liu Z, Zou H, Stohl W, Zheng SG. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann Rheum Dis. 2012 Sep; 71(9):1567-72. View in: PubMed

Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis. 2012 Aug; 71(8):1289-96. View in: PubMed

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012 Aug; 39(8):1632-40. View in: PubMed

Stohl W. Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development? Curr Rheumatol Rep. 2012 Aug; 14(4):303-9. View in: PubMed

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul; 64(7):2328-37. View in: PubMed

Jacob CO, Guo S, Jacob N, Pawar RD, Putterman C, Quinn WJ, Cancro MP, Migone TS, Stohl W. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012 May; 64(5):1610-9. View in: PubMed

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar; 71(3):351-7. View in: PubMed

Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012; 30(1):69-77. View in: PubMed

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30. View in: PubMed

Stohl W, Scholz JL, Cancro MP. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol. 2011 May; 23(3):305-10. View in: PubMed

Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, Jacob CO, Stohl W. B Cell and BAFF dependence of IFN-a-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011 Apr 15; 186(8):4984-93. View in: PubMed

Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE. Antibody-mediated coengagement of Fc?RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1; 186(7):4223-33. View in: PubMed

Zhou X, Xia Z, Lan Q, Wang J, Su W, Han YP, Fan H, Liu Z, Stohl W, Zheng SG. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One. 2011; 6(8):e23629. View in: PubMed

Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(4):228. View in: PubMed

Stohl W, Jacob N, Guo S, Morel L. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010 Aug; 62(8):2432-42. View in: PubMed

Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010 Feb; 43(1):84-97. View in: PubMed

Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb; 62(2):392-401. View in: PubMed

Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010; 12(2):111. View in: PubMed

Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K, Shaham B, Phei WC, Garza J, Bernstein B, Stohl W. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009 Nov; 60(11):3400-9. View in: PubMed

Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Koss MN, Stohl W, Kovats S, Jacob CO. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol. 2009 Nov 1; 183(9):6021-9. View in: PubMed

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78. View in: PubMed

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51. View in: PubMed

Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol. 2009 Feb 15; 182(4):2532-41. View in: PubMed

Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009; 11(5):R143. View in: PubMed

Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008 Aug; 58(8):2453-9. View in: PubMed

Stohl W, Jacob N, Quinn WJ, Cancro MP, Gao H, Putterman C, Gao X, Pricop L, Koss MN. Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol. 2008 Jul 1; 181(1):833-41. View in: PubMed

Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109. View in: PubMed

Looney RJ, Stohl W. New and promising treatments for rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007 Jul; 36(7 Suppl):18-23. View in: PubMed

Stohl W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):351-8. View in: PubMed

Schaller M, Stohl W, Benoit V, Tan SM, Johansen L, Ditzel HJ. Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochem Biophys Res Commun. 2006 Oct 20; 349(2):838-45. View in: PubMed

Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. 2006 Oct; 121(1):1-12. View in: PubMed

Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006 Aug 15; 177(4):2671-80. View in: PubMed

Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol. 2006 Mar 15; 176(6):3321-9. View in: PubMed

Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006 Mar; 54(3):723-32. View in: PubMed

Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006; 8(1):R6. View in: PubMed

Stohl W, Xu D, Kim KS, Tedder TF, Sato S. Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. Clin Immunol. 2005 Sep; 116(3):257-64. View in: PubMed

Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, Metzger TE, Bixler SA, Hong YS, Ambrose CM, Mackay F, Morel L, Putterman C, Kotzin BL, Kalled SL. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005 Jul; 52(7):2080-91. View in: PubMed

Stohl W. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun. 2005; 8:289-304. View in: PubMed

Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71. View in: PubMed

Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004 Sep; 63(9):1096-103. View in: PubMed

Stohl W, Xu D, Kim KS, David CS, Allison JP. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904. View in: PubMed

Stohl W, Xu D, Metzger TE, Kim KS, Morel L, Kotzin BL. Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis Rheum. 2004 Jul; 50(7):2227-39. View in: PubMed

Stohl W. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets. 2004 Jun; 8(3):177-89. View in: PubMed

Stohl W. A therapeutic role for BLyS antagonists. Lupus. 2004; 13(5):317-22. View in: PubMed

Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003 Dec; 48(12):3475-86. View in: PubMed

Kim KS, Jacob N, Stohl W. In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin Immunol. 2003 Sep; 108(3):182-9. View in: PubMed

Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003 Apr; 48(4):982-92. View in: PubMed

Stohl W. SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther. 2003; 5(3):136-8. View in: PubMed

Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002 Oct 15; 169(8):4314-21. View in: PubMed

Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol. 2002 Sep; 14(5):522-8. View in: PubMed

Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep. 2002 Aug; 4(4):345-50. View in: PubMed

Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V, Ferrara DE, Labat K, Sattler FR, Pierangeli SS, Hilbert DM. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol. 2002 Aug; 104(2):115-22. View in: PubMed

Powered bySC CTSI